Anacor Pharmaceuticals, Inc. (ANAC) Reports 2012 Fourth Quarter and Year-End Financial Results  
3/15/2013 6:24:38 AM

Anacor Pharmaceuticals (NASDAQ:ANAC) announced today its financial results for the fourth quarter and year ended December 31, 2012.

“With the positive data from both Phase 3 trials of tavaborole for the treatment of onychomycosis, we anticipate filing an NDA around the middle of this year, and we will continue to evaluate commercialization options to maximize the value of tavaborole,” said David Perry, CEO of Anacor Pharmaceuticals.